Modulation of CCR5 density with low doses of the transplant drug Rapamycin sensitizes Vicriviroc-resistant R5 HIV-1

被引：0
|
作者：
Heredia, Alonso [1 ]
机构：
[1] Inst Human Virol, Baltimore, MD USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2009年 / 51卷
关键词：
D O I：
10.1097/01.qai.0000351153.08940.9f
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
198
引用
收藏
页码：124 / 124
页数：1
相关论文
共 50 条
  • [21] Two HIV-1 Variants Resistant to Small Molecule CCR5 Inhibitors Differ in How They Use CCR5 for Entry
    Berro, Reem
    Sanders, Rogier W.
    Lu, Min
    Klasse, Per J.
    Moore, John P.
    PLOS PATHOGENS, 2009, 5 (08)
  • [22] An aptamer that neutralizes R5 strains of HIV-1 binds to core residues of gp120 in the CCR5 binding site
    Cohen, Carla
    Forzan, Mario
    Sproat, Brian
    Pantophlet, Ralph
    McGowan, Ian
    Burton, Dennis
    James, William
    VIROLOGY, 2008, 381 (01) : 46 - 54
  • [23] Adaptation of HIV-1 to cells with low expression of the CCR5 coreceptor
    Espy, Nicole
    Pacheco, Beatriz
    Sodroski, Joseph
    VIROLOGY, 2017, 508 : 90 - 107
  • [24] In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc:: findings from ACTG A5211
    Tsibris, A. M. N.
    Gulick, R. M.
    Su, Z.
    Hughes, M. D.
    Flexner, C.
    Wilkin, T.
    Gross, R.
    Hirsch, M.
    Skolnick, P. R.
    Coakley, E.
    Greaves, W. L.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S15 - S15
  • [25] In vivo emergence of HIV-1 resistance to the CCR5 antagonist vicriviroc:: findings from ACTG A5211
    Tsibris, A. M. N.
    Gulick, R. M.
    Su, Z.
    Hughes, M. D.
    Flexner, C.
    Wilkin, T.
    Gross, R.
    Hirsch, M.
    Skolnick, P. R.
    Coakley, E.
    Greaves, W. L.
    Kuritzkes, D. R.
    ANTIVIRAL THERAPY, 2007, 12 : S15 - S15
  • [26] CRISPR/Cas9 genome editing of CCR5 combined with C46 HIV-1 fusion inhibitor for cellular resistant to R5 and X4 tropic HIV-1
    Khamaikawin, Wannisa
    Saisawang, Chonticha
    Tassaneetrithep, Boonrat
    Bhukhai, Kanit
    Phanthong, Phetcharat
    Borwornpinyo, Suparerk
    Phuphuakrat, Angsana
    Pasomsub, Ekawat
    Chaisavaneeyakorn, Sujittra
    Anurathapan, Usanarat
    Apiwattanakul, Nopporn
    Hongeng, Suradej
    SCIENTIFIC REPORTS, 2024, 14 (01):
  • [27] The EBI2 receptor is coexpressed with CCR5 in CD4+ T cells and boosts HIV-1 R5 replication
    Guigues, Adeline
    Gimenez, Sandrine
    Mettling, Clement
    Maurel, Damien
    Doumazane, Etienne
    Prezeau, Laurent
    Francois, Vincent
    Corbeau, Pierre
    AIDS, 2024, 38 (10) : 1449 - 1459
  • [28] CCR5 antagonist-resistant HIV-1 entry kinetics as a function of CD4 and CCR5 surface expression
    Putcharoen, O.
    Lee, S-H
    Henrich, T. J.
    Vanichanan, J.
    Kuritzkes, D. R.
    Tsibris, A. M. N.
    ANTIVIRAL THERAPY, 2011, 16 : A64 - A64
  • [29] HIV-1 clones resistant to a small molecule CCR5 inhibitor use the inhibitor-bound form of CCR5 for entry
    Pugach, Pavel
    Marozsan, Andre J.
    Ketas, Thomas J.
    Landes, Elissa L.
    Moore, John P.
    Kuhmann, Shawn E.
    VIROLOGY, 2007, 361 (01) : 212 - 228
  • [30] Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention
    Latinovic, Olga
    Le, Nhut
    Reitz, Marvin
    Pal, Ranajit
    DeVico, Anthony
    Foulke, James S.
    Redfield, Robert R.
    Heredia, Alonso
    AIDS, 2011, 25 (09) : 1232 - 1235
12345